Maxim Group analyst Jason McCarthy maintained a Buy rating on Capricor Therapeutics (CAPR – Research Report) yesterday and set a price target ...

HC Wainwright reissued their buy rating on shares of Capricor Therapeutics (NASDAQ:CAPR – Free Report) in a research note ...

Capricor Therapeutics (CAPR – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Joseph ...

Shares of Capricor Therapeutics Inc (NASDAQ:CAPR – Get Free Report) saw strong trading volume on Friday . 413,080 shares were traded during trading, a decline of 47% from the previous session’s volume ...

Capricor Therapeutics (CAPR) stock gains as the company completes the U.S. marketing application for lead drug deramiocel in ...

Ratings for Capricor Therapeutics (NASDAQ:CAPR) were provided by 7 analysts in the past three months, showcasing a mix of bullish and bearish perspectives. Summarizing their recent assessments ...

Capricor Therapeutics has completed its US marketing application for deramiocel, a cell therapy the US biotech hopes will ...

Capricor stock gains 8% upon completing the rolling submission of the BLA for its lead asset, deramiocel, to treat DMD cardiomyopathy in the United States.

Capricor Therapeutics seeks US FDA approval for deramiocel for the treatment of Duchenne muscular dystrophy: San Diego Saturday, January 4, 2025, 15:00 Hrs [IST] Capricor Therapeu ...

Capricor Therapeutics (CAPR) announced the completion of the submission of its Biologics License Application, BLA, to the U.S. Food and Drug Administration, FDA, seeking full approval for ...